Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Clinical Psychopharmacology

• Publication date

  2002-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/00004714-200206000-00003PMID 12006893
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

  2001cited by this paper
• Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities

  2001cited by this paper
• Psychiatric Medication for Older Adults: The Concise Guide

  2001cited by this paper
• Weight change and atypical antipsychotic treatment in patients with schizophrenia.

  2001cited by this paper
• Brain dopamine and obesity.

  2001cited by this paper
• 159. Weight gain and response to olanzapine treatment in schizophrenia

  2000cited by this paper
• Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.

  2000cited by this paper
• Atypical antipsychotics and weightgain — a systematic review

  2000cited by this paper
• H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.

  2000cited by this paper
• Weight gain and antipsychotic medication.

  2000cited by this paper
• Weight gain from novel antipsychotic drugs: need for action.

  2000cited by this paper
• Body weight and leptin plasma levels during treatment with antipsychotic drugs.

  1999cited by this paper
• Recent advances in basic obesity research.

  1999cited by this paper
• Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.

  1999cited by this paper
• Novel antipsychotics: comparison of weight gain liabilities.

  1999cited by this paper
• Weight gain associated with use of psychotropic medications.

  1999cited by this paper
• Body weight gain induced by antipsychotic drugs: mechanisms and management

  1999cited by this paper
• Olanzapine: weight gain and therapeutic efficacy.

  1999cited by this paper
• Clinical practice guidelines: praise and problems.

  1999cited by this paper
• Weight gain associated with antipsychotic drugs.

  1999cited by this paper
• Antipsychotic-induced weight gain: a comprehensive research synthesis.

  1999cited by this paper
• Weight gain: side effect of atypical neuroleptics?

  1999cited by this paper
• 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

  1998cited by this paper
• Effects of phentermine on striatal dopamine and serotonin release in conscious rats:In vivo microdialysis study

  1998cited by this paper
• Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.

  1997cited by this paper
• Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study.

  1996cited by this paper
• The concentrations of monoamine metabolites and neuropeptides in the cerebrospinal fluid of obese women with different body fat distribution.

  1996cited by this paper
• Prise de poids et clozapine

  1996cited by this paper
• High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.

  1996cited by this paper
• Genetic variants of the human obesity (OB) gene: association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene.

  1996cited by this paper
• Differential effect of clozapine on weight: a controlled study.

  1996cited by this paper
• Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks.

  1995cited by this paper
• Weight gain associated with neuroleptic medication: a review.

  1995cited by this paper
• Clozapine and weight gain.

  1994cited by this paper
• Neurochemical mechanism of action of anorectic drugs.

  1993cited by this paper
• Serotonin may play a role in the anorexia induced by amphetamine injections into the lateral hypothalamus.

  1992cited by this paper
• Clozapine-induced weight gain: prevalence and clinical relevance.

  1992cited by this paper
• The mechanism of action of novel antipsychotic drugs.

  1991cited by this paper
• The role of serotonin in schizophrenia.

  1988cited by this paper
• A Clinical Trial of the Efficacy and Acceptability of d-Fenfluramine in the Treatment of Neuroleptic-induced Obesity

  1988cited by this paper
• Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons.

  1975cited by this paper
• NOSIE--30: history and current status of its use in pharmacopsychiatric research.

  1974cited by this paper

• Obesity Associated With Symptomatic Remission in Clozapine-Treated Individuals With Treatment-Resistant Schizophrenia.

  2025cites this paper
• Clozapine-associated Weight Loss: A Case Series.

  2025cites this paper
• Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders.

  2024cites this paper
• Machine learning prediction model of the treatment response in schizophrenia reveals the importance of metabolic and subjective characteristics.

  2024cites this paper
• Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis

  2024cites this paper
• Divergent patterns of genetic overlap between severe mental disorders and metabolic markers

  2024cites this paper
• Metabolic effects of atypical antipsychotics: Molecular targets

  2023cites this paper
• Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia.

  2023cites this paper
• Positive Symptoms in Antipsychotic-naïve Schizophrenia are Associated with Increased Body Mass Index after Treatment

  2021cites this paper
• Drug Resistance in Diabetes

  2021cites this paper
• Predictive value of cardiometabolic biomarkers and depressive symptoms for symptom severity and quality of life in patients with psychotic disorders.

  2021cites this paper
• Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment

  2021cites this paper
• Comparison of three different exercise training modalities (aerobic, strength and mixed) in patients with schizophrenia: study protocol for a multicentre randomised wait-list controlled trial

  2021cites this paper
• Sex-specific Association of Antipsychotic-induced Weight Gain and Treatment Response for Antipsychotic-Naive First Episode Schizophrenia Patients: A Prospective 8-week Longitudinal Study

  2021cites this paper
• Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis

  2020cites this paper
• Lipid effects during antipsychotic drug treatment and their relevance for clinical outcomes

  2020cites this paper
• Antipsychotic-Induced Weight Gain and Clinical Improvement: A Psychiatric Paradox

  2020cites this paper
• The association of change in serum cholesterol levels and clinical treatment response in patients with schizophrenia: a prospective, randomized and open-label study

  2019cites this paper
• Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months.

  2019cites this paper
• Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders.

  2019cites this paper
• Adjunctive Reboxetine for Schizophrenia: Meta-analysis of Randomized Double-blind, Placebo-controlled Trials

  2019cites this paper
• The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment

  2018influential citation
• Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study

  2018cites this paper
• Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis

  2018cites this paper
• Altered reward anticipation: Potential explanation for weight gain in schizophrenia?

  2017cites this paper
• Metabolic Syndrome Prevalence and Reduction in Inmates Prescribed Antipsychotic Medications

  2017cites this paper
• Inverse association between negative symptoms and body mass index in chronic schizophrenia.

  2017cites this paper
• Preventing and De-escalating Aggressive Behavior Among Adult Psychiatric Patients: A Systematic Review of the Evidence.

  2017influential citation
• Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis.

  2017cites this paper
• Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject

  2016cites this paper
• Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.

  2016cites this paper
• Haloperidol for long-term aggression in psychosis.

  2016cites this paper
• Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?

  2016cites this paper
• The Genetics of Antipsychotic Response: Pharmacogenetic and Pharmacogenomic Investigations and Clinical Applications

  2016cites this paper
• Body mass index and blood glucose in psychiatric and general practice populations

  2016cites this paper
• Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia

  2016cites this paper
• Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment.

  2016cites this paper
• Weight Gain on Antipsychotic Medication Is Associated With Sustained Use Among Veterans With Schizophrenia

  2015cites this paper
• Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms.

  2015cites this paper
• A Study on Changes of Metabolic Parameters with Antipsychotic Treatment in Schizophrenic Patients : 1 Year Prospective Natualistic Study

  2015cites this paper
• Association between serum lipids and membrane fatty acids and clinical characteristics in patients with schizophrenia

  2015cites this paper
• Obesity and Psychopathology of Inpatients with Schizophrenia

  2015cites this paper
• Association between antipsychotic-induced metabolic side-effects and clinical improvement: a review on the Evidence for "metabolic threshold".

  2014influential citation
• Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

  2014cites this paper
• Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity

  2014cites this paper
• Body mass index identified as an independent predictor of psychiatric readmission.

  2014cites this paper
• Body Mass Index, Obesity, and Psychopathology in Patients With Schizophrenia

  2014cites this paper
• Nutritional Status of Schizophrenic Patients at Department of Psychiatry in Dr. Hasan Sadikin General Hospital

  2014cites this paper
• Antipsychotic induced metabolic changes & treatment response: a prospective study.

  2014cites this paper
• Clozapine safety, 40 years later.

  2014cites this paper
• [Efficacy of behavioural lifestyle interventions for weight management of psychiatric patients].

  2013cites this paper
• Associations Among Obesity, Acute Weight Gain, and Response to Treatment with Olanzapine in Adolescent Schizophrenia

  2013cites this paper
• EARLY PREDICTION OF LIPID DERANGEMENT DURING ANTIPSYCHOTIC (OLANZAPINE) TREATMENT

  2013cites this paper
• Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.

  2013cites this paper
• Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome.

  2013cites this paper
• A Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?

  2013cites this paper
• Schizophrenia: Metabolic aspects of aetiology, diagnosis and future treatment strategies

  2013cites this paper
• Efficacité des programmes de modifications des habitudes de vie pour la gestion de poids des personnes avec des troubles psychiatriques

  2013cites this paper
• Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1).

  2013cites this paper
• Amisulpride‐associated acute onset of metabolic syndrome in a schizophrenia patient

  2013cites this paper
• Second-Generation Antipsychotic Use in Schizophrenia and Associated Weight Gain: A Critical Review and Meta-Analysis of Behavioral and Pharmacologic Treatments

  2012cites this paper
• Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.

  2012cites this paper
• [Metabolic syndrome in patients with schizophrenia independently from atypical antipsychotics intake].

  2012cites this paper
• Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients

  2012cites this paper
• Combination and high-dose atypical antipsychotic therapy in patients with schizophrenia: systematic review.

  2012cites this paper
• Comparing tolerability profile of second generation antipsychotics in schizophrenia and affective disorders : a meta-analysis

  2012cites this paper
• Lipid Effects of Psychiatric Medications

  2012cites this paper
• Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders

  2012cites this paper
• The association between weight change and symptom reduction in the CATIE schizophrenia trial.

  2011influential citation
• Metabolic Syndrome in Severe Mental Disorders

  2011cites this paper
• Gilles de la Tourette syndrome: the complexities of phenotype and treatment.

  2011cites this paper
• Factors Associated with Response to Clozapine in Schizophrenia: A Review

  2011cites this paper
• Abnormalities in metabolism and hypothalamic-pituitary-adrenal axis function in schizophrenia.

  2011cites this paper
• Atypical Antipsychotics Cause an Acute Increase in Cutaneous Hand Blood Flow in Patients with Schizophrenia and Schizoaffective Disorder

  2011cites this paper
• Factors associated with response to clozapine in schizophrenia: a review.

  2011cites this paper
• Impact of patients' preexisting metabolic risk factors on the choice of antipsychotics by office-based physicians.

  2011cites this paper
• Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder

  2011cites this paper
• Relation between weight gain and clinical improvement: is there a metabolic threshold for second generation antipsychotics?

  2011cites this paper
• Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.

  2011cites this paper
• Clozapine safety, 35 years later.

  2011cites this paper
• Importance of the Concept of Metabolic Syndrome in Psychiatry : Contribution of the Disease to Risk of Metabolic Syndrome

  2011cites this paper
• Association between symptom improvement and change of body mass index, lipid profile, and leptin, ghrelin, and cholecystokinin levels during 6-week olanzapine treatment in patients with first-episode psychosis.

  2010cites this paper
• Antihistaminerge Antipsychotika verursachen Gewichtszunahme

  2010cites this paper
• Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report

  2010cites this paper
• A Longitudinal Study on the Impact of Antipsychotic Treatment on Serum Leptin in Schizophrenia

  2010cites this paper
• [Antihistaminergic antipsychotics cause weight gain].

  2010cites this paper
• Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.

  2010cites this paper
• A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.

  2010cites this paper
• Clozapine versus other atypical antipsychotics for schizophrenia.

  2010cites this paper
• Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design.

  2010cites this paper
• Psychotropic medication use mediates the relationship between mood and anxiety disorders and obesity: findings from a nationally representative sample.

  2010cites this paper
• Predictors of switching antipsychotic medications in the treatment of schizophrenia

  2010cites this paper
• Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics.

  2010cites this paper
• Olanzapine versus other atypical antipsychotics for schizophrenia.

  2010cites this paper
• Chronic olanzapine, serotonin receptors, and subsequent serotonin toxicity.

  2010cites this paper
• ACOMPANHAMENTO DOS ÍNDICES ANTROPOMÉTRICOS EM ADOLESCENTES INTERNADOS EM CLÍNICA PARA ABSTINÊNCIA DO USO DE CRACK

  2010cites this paper
• Obesity, serious mental illness and antipsychotic drugs

  2009cites this paper
• Contributing factors to weight gain during long‐term treatment with second‐generation antipsychotics. A systematic appraisal and clinical implications

  2009cites this paper
• Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.

  2009cites this paper
• Weight management and chronic disease

  2009cites this paper